Literature DB >> 29302853

Progesterone Receptor (PGR) Gene Variants Associated with Breast Cancer and Associated Features: a Case-Control Study.

Rabeb M Ghali1,2, Maryam A Al-Mutawa3, Bashayer H Ebrahim3, Hanen H Jrah1, Sonia Zaied4, Hanen Bhiri4, Fahmi Hmila5, Touhami Mahjoub1, Wassim Y Almawi6.   

Abstract

Insofar as altered estrogen receptor-progesterone receptor (PR) expression contribute to breast cancer pathogenesis, previous studies examined the association of genetic variation in PR gene (PGR) with breast cancer, but with mixed outcome. We evaluated the association between PGR variants, and breast cancer and associated features. A retrospective case-control study involving 183 female breast cancer patients, and 222 control women. PGR genotyping was done by real-time PCR. Minor allele frequencies of rs1042838, rs590688, and rs10895068 PGR gene polymorphisms were significantly higher in breast cancer patients compared to controls. Patients carrying rs1042838 G/T, rs590688 C/C, and rs10895068 G/A genotypes had higher risk of breast cancer, while carriage of rs3740753 G/G genotype was associated with marginal reduction in breast cancer risk. In addition, carriage of rs1042839, rs3740753, and rs10895068 minor allele was associated with Her2 status, while rs3740753 and rs10895068 were associated with effective hormone replacement therapy. Furthermore, carriage of rs10895068 minor allele in breast cancer women were also associated with age at first pregnancy, hormone receptor (RH) status, and previous use of oral contraceptives. PGR haploview analysis documented moderate-strong linkage disequilibrium (non-random association of alleles at different loci) between 7 of the 8 tested PGR SNPs, thus allowing construction of 7-locus PGR haplotypes. Two haplotypes, ATGCCGA and GTGCCGA, both containing rs590688, were positively associated with breast cancer, thus assigning a breast cancer-susceptible nature to these haplotypes. PGR rs1042838, rs590688, and rs10895068, and ATGCCGA and GTGCCGA haplotypes are related with increased breast cancer susceptibility in Tunisian women.

Entities:  

Keywords:  Breast cancer; Haplotypes; Mutation; Progesterone; Progesterone receptor

Mesh:

Substances:

Year:  2018        PMID: 29302853     DOI: 10.1007/s12253-017-0379-z

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  32 in total

1.  No association between the progesterone receptor gene +331G/A polymorphism and breast cancer.

Authors:  Heather Spencer Feigelson; Carmen Rodriguez; Eric J Jacobs; W Ryan Diver; Michael J Thun; Eugenia E Calle
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-06       Impact factor: 4.254

2.  A phenotype from tumor stroma based on the expression of metalloproteases and their inhibitors, associated with prognosis in breast cancer.

Authors:  Noemí Eiró; Belen Fernandez-Garcia; Julio Vázquez; José M Del Casar; Luis O González; Francisco J Vizoso
Journal:  Oncoimmunology       Date:  2015-01-29       Impact factor: 8.110

Review 3.  Current Status and Future Projections of Breast Cancer in Asia.

Authors:  Lei Fan; Paul E Goss; Kathrin Strasser-Weippl
Journal:  Breast Care (Basel)       Date:  2015-12-15       Impact factor: 2.860

4.  Clarifying the PROGINS allele association in ovarian and breast cancer risk: a haplotype-based analysis.

Authors:  Celeste Leigh Pearce; Joel N Hirschhorn; Anna H Wu; Noël P Burtt; Daniel O Stram; Stanton Young; Laurence N Kolonel; Brian E Henderson; David Altshuler; Malcolm C Pike
Journal:  J Natl Cancer Inst       Date:  2005-01-05       Impact factor: 13.506

5.  No association between a progesterone receptor gene promoter polymorphism (+331G>A) and breast cancer risk in Caucasian women: evidence from a literature-based meta-analysis.

Authors:  Ke-Da Yu; Ao-Xiang Chen; Zhi-Ming Shao
Journal:  Breast Cancer Res Treat       Date:  2010-01-14       Impact factor: 4.872

6.  Polymorphisms in genes involved in sex hormone metabolism, estrogen plus progestin hormone therapy use, and risk of postmenopausal breast cancer.

Authors:  Brenda Diergaarde; John D Potter; Eldon R Jupe; Sharmila Manjeshwar; Craig D Shimasaki; Thomas W Pugh; Daniele C Defreese; Bobby A Gramling; Ilonka Evans; Emily White
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-07       Impact factor: 4.254

7.  Prognostic significance of oestrogen and progestogen receptor activities in breast cancer.

Authors:  R A Hawkins; G White; N J Bundred; J M Dixon; W R Miller; H J Stewart; A P Forrest
Journal:  Br J Surg       Date:  1987-11       Impact factor: 6.939

8.  Progesterone signaling mechanisms in brain and behavior.

Authors:  Shaila K Mani; Mario G Oyola
Journal:  Front Endocrinol (Lausanne)       Date:  2012-01-30       Impact factor: 5.555

9.  The progesterone receptor Val660-->Leu polymorphism and breast cancer risk.

Authors:  Immaculata De Vivo; Susan E Hankinson; Graham A Colditz; David J Hunter
Journal:  Breast Cancer Res       Date:  2004-09-22       Impact factor: 6.466

Review 10.  Expression and transcriptional activity of progesterone receptor A and progesterone receptor B in mammalian cells.

Authors:  J Dinny Graham; Christine L Clarke
Journal:  Breast Cancer Res       Date:  2002-07-02       Impact factor: 6.466

View more
  9 in total

1.  Genetic variants in the genes of the sex steroid hormone metabolism and depressive symptoms during and after pregnancy.

Authors:  Michael O Schneider; Jutta Pretscher; Tamme W Goecke; Lothar Häberle; Anne Engel; Johannes Kornhuber; Anna Eichler; Arif B Ekici; Matthias W Beckmann; Peter A Fasching; Eva Schwenke
Journal:  Arch Gynecol Obstet       Date:  2022-06-10       Impact factor: 2.344

2.  Association of the PROGINS PgR polymorphism with susceptibility to female reproductive cancer: A meta-analysis of 30 studies.

Authors:  Chen Zhou; Xiangman Zou; Xiaosha Wen; Zifen Guo
Journal:  PLoS One       Date:  2022-07-15       Impact factor: 3.752

Review 3.  Estrogens, Cancer and Immunity.

Authors:  Izabela Orzołek; Jan Sobieraj; Joanna Domagała-Kulawik
Journal:  Cancers (Basel)       Date:  2022-04-30       Impact factor: 6.575

4.  Progesterone Receptor Gene Variants in Metastatic Estrogen Receptor Positive Breast Cancer.

Authors:  Amy M Fowler; Kelley Salem; Michael DeGrave; Irene M Ong; Shane Rassman; Ginny L Powers; Manoj Kumar; Ciara J Michel; Aparna M Mahajan
Journal:  Horm Cancer       Date:  2020-01-16       Impact factor: 3.869

5.  A Birth Cohort Study on the Genetic Modification of the Association of Prenatal Methylmercury With Child Cognitive Development.

Authors:  Jordi Julvez; George Davey Smith; Susan Ring; Philippe Grandjean
Journal:  Am J Epidemiol       Date:  2019-10-01       Impact factor: 4.897

6.  Study on the Multitarget Mechanism and Active Compounds of Essential Oil from Artemisia argyi Treating Pressure Injuries Based on Network Pharmacology.

Authors:  Shu-Ting Lu; Lu-Lu Tang; Ling-Han Zhou; Ying-Tao Lai; Lan-Xing Liu; Yifan Duan
Journal:  Evid Based Complement Alternat Med       Date:  2022-01-19       Impact factor: 2.650

7.  Impacts of LOC105371267 Variants on Breast Cancer Susceptibility in Northern Chinese Han Females: A Population-Based Case-Control Study.

Authors:  Linna Peng; Congmei Huang; Shishi Xing; Dandan Li; Chunjuan He; Yongjun He; Wei Yang; Tianbo Jin; Li Wang
Journal:  J Oncol       Date:  2021-08-28       Impact factor: 4.375

8.  Genetic Factors of Idiopathic Gigantomastia: Clinical Implications of Aromatase and Progesterone Receptor Polymorphisms.

Authors:  Anna Kasielska-Trojan; Michał Pietrusiński; Magdalena Bugaj-Tobiasz; Jerzy Strużyna; Maciej Borowiec; Bogusław Antoszewski
Journal:  J Clin Med       Date:  2022-01-27       Impact factor: 4.241

9.  Exploring the molecular targets and mechanisms of [10]-Gingerol for treating triple-negative breast cancer using bioinformatics approaches, molecular docking, and in vivo experiments.

Authors:  Ping Huang; Peijuan Zhou; Yuqi Liang; Jiahua Wu; Guosong Wu; Rui Xu; Yan Dai; Qianqian Guo; Hai Lu; Qianjun Chen
Journal:  Transl Cancer Res       Date:  2021-11       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.